	2012 Mar 31	R 2013 Mar 31	2014 Mar 31	2015 Mar 31	C 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	R 2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Total Revenue	4,021	5,012	6,005	6,630	7,650	9,186	9,103	9,865	10,641	10,944	12,305	11,583	11,813	13,322	16,983
Cost of Operating Revenue	1,443	2,006	2,364	2,498	2,961	3,598	3,906	4,476	4,626	4,771	5,466	5,268	5,585	5,375	5,321
Gross Profit	2,577	3,006	3,641	4,132	4,688	5,588	5,197	5,390	6,015	6,173	6,839	6,316	6,228	7,947	11,662
Gross Margin	64.1	60.0	60.6	62.3	61.3	60.8	57.1	54.6	56.5	56.4	55.6	54.5	52.7	59.7	68.7
Total Operating Expenses	3,404	4,091	4,904	5,711	6,486	7,726	7,840	8,826	9,359	9,303	10,465	10,517	11,200	11,456	-
Operating Profit	616	921	1,101	919	1,164	1,460	1,263	1,039	1,282	1,641	1,840	1,066	613	1,865	-
Operating Margin	15.3	18.4	18.3	13.9	15.2	15.9	13.9	10.5	12.0	15.0	15.0	9.2	5.2	14.0	-
Financing Income/(Expense) - Net	-138	-189	-192	-345	-171	-219	-277	-332	-377	-350	-200	-138	-510	-135	209
Profit before Taxes	488	739	697	594	1,005	1,260	1,067	1,258	1,096	1,382	1,441	240	36	1,399	1,985
Income Taxes	24	111	151	119	303	344	293	366	320	412	448	329	1,867	352	623
Profit after Tax	460	620	542	475	702	916	774	892	776	970	942	297	-1,502	1,047	-
PAT Margin	11.4	12.4	9.0	7.2	9.2	10.0	8.5	9.0	7.3	8.9	7.7	2.6	-12.7	7.9	-
EPS - Basic - ex Extraordinary Items	17.03	22.91	20.01	17.52	25.01	32.46	27.44	31.60	27.50	34.38	33.37	-6.01	-67.30	37.11	-
EPS - Diluted - ex Extraordinary Items	17.01	22.89	20.00	17.52	25.00	32.45	27.43	31.60	27.50	34.38	33.37	-6.01	-67.30	37.10	-
EBIT	616	921	1,101	919	1,164	1,460	1,263	1,039	1,282	1,641	1,840	1,066	613	1,865	1,315
EBITDA	714	1,048	1,318	1,179	1,433	2,037	1,617	1,586	1,699	2,084	2,497	1,677	1,244	2,351	1,889
EBITDA Margin	17.8	20.9	21.9	17.8	18.7	22.2	17.8	16.1	16.0	19.0	20.3	14.5	10.5	17.7	11.1

Balance Sheet

Abridged

Understanding Balance Sheet

Glenmark Pharmaceuticals Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	C 2013 Mar 31	C 2014 Mar 31	R 2015 Mar 31	R 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	C 2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	2,947	3,727	4,763	5,323	5,906	6,875	6,989	6,697	6,804	7,360	8,282	8,424	7,428	9,295	11,300
Long-Term Investments	30	32	33	36	46	52	15	30	25	25	50	45	790	56	110
Property Plant & Equipment - Net	1,299	1,555	1,763	2,057	2,462	2,745	3,208	3,640	4,068	4,176	4,612	4,195	3,537	3,861	3,772
Total Non-Current Assets	2,936	3,444	3,871	4,364	4,930	5,337	6,032	6,982	7,881	8,244	8,801	10,948	6,931	6,754	8,608
Total Assets	5,883	7,171	8,634	9,688	10,836	12,212	13,021	13,679	14,685	15,604	17,083	19,372	14,359	16,050	19,908
Total Current Liabilities	1,902	2,201	2,949	3,711	4,002	2,704	3,288	4,021	4,126	4,201	4,689	4,546	5,819	5,967	6,376
Long Term Debt	1,312	1,920	2,429	2,574	2,487	4,536	4,142	3,574	4,274	4,113	2,772	4,029	152	699	-
Total Non-Current Liabilities	1,555	2,182	2,688	2,976	2,564	4,569	4,144	3,663	4,489	4,338	2,956	4,986	692	1,233	3,020
Total Liabilities	3,457	4,384	5,637	6,687	6,566	7,273	7,432	7,684	8,615	8,539	7,645	9,532	6,511	7,200	9,396
Total Shareholders' Equity	2,402	2,763	2,983	3,000	4,270	4,939	5,589	5,995	6,071	7,065	9,087	9,474	7,848	8,849	10,512
Minority Interest	25	24	13	0	0	0	0	0	0	0	351	365	0	0	0
Total Equity	2,427	2,787	2,997	3,000	4,270	4,939	5,589	5,995	6,070	7,064	9,438	9,839	7,848	8,849	10,512
Total Liabilities & Equity	5,883	7,171	8,634	9,688	10,836	12,212	13,021	13,679	14,685	15,604	17,083	19,372	14,359	16,050	19,908

Cash Flow

Abridged

Understanding Cash Flow Statement

Glenmark Pharmaceuticals Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	C 2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	683	774	956	572	781	1,354	1,136	922	969	1,226	1,429	1,411	32	1,552	3,892
Working Capital - Increase/(Decrease)	-35	-268	-290	-267	-608	-862	309	136	127	-386	-561	-1,074	-797	-2,529	-447
Net CF from Operating Activities	648	506	666	305	173	493	1,445	1,058	1,096	841	868	337	-765	-976	3,299
Capital Expenditures - Net	283	468	373	538	889	733	1,023	1,234	776	675	786	550	913	748	-2
Net CF from Investing Activities	-284	-468	-375	-542	-889	-731	-1,023	-702	-789	-678	-343	-552	4,544	-40	-
Dividends Paid - Cash - Total	13	64	63	63	68	68	68	68	69	70	93	137	118	70	141
Stock - Issuance/(Retirement) - Net	4	6	13	2	935	0	-	-	-	-	1,012	-	1	-	-
Debt - LT & ST - Issuance/(Retirement) - Total	-156	448	205	481	11	794	-188	-369	-75	-78	-1,132	523	-3,273	1,078	-2,246
Net Cash Flow from Financing Activities	-198	342	96	378	879	727	-255	-469	-143	-148	-270	234	-3,389	978	-
Free Cash Flow to Equity	208	485	498	248	-704	554	234	-546	245	88	-1,050	310	-4,951	-646	1,056
Free Operating CF net dividend	350	-30	226	-303	-785	-324	332	-249	95	-5	-15	-407	-1,798	-1,797	3,158
Free Operating CF	362	35	289	-239	-717	-256	400	-181	164	66	78	-271	-1,680	-1,727	3,299

Business Segment Analysis

FY End:

Mar 25

Glenmark Pharmaceuticals Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmaceuticals (100.0%)₹ 750.72 Cr

Revenue / Sales

Pharmaceuticals (100.0%)₹ 13,321.74 Cr

Assets

Pharmaceuticals (100.0%)₹ 16,049.55 Cr

Operating Income

Pharmaceuticals (100.0%)₹ 1,865.37 Cr

Regional Segment Analysis

FY End:

Mar 25

Glenmark Pharmaceuticals Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

India (33.7%)₹ 4,484.48 CrNorth America (22.6%)₹ 3,017.17 CrEurope (22.6%)₹ 3,006.29 CrLatin America (21.1%)₹ 2,813.80 Cr

Assets

India (40.2%)₹ 2,014.66 CrNorth America (36.0%)₹ 1,801.04 CrEurope (19.4%)₹ 972.40 CrLatin America. (4.4%)₹ 220.07 Cr

Historical Segment Analysis

Track how Glenmark Pharmaceuticals Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31

Pharmaceuticals	932	775	790	608	915	751

Frequently Asked Questions

What is the revenue of Glenmark Pharmaceuticals Ltd.?

The latest trailing twelve month revenue of Glenmark Pharmaceuticals Ltd. is ₹ 16,982.50 Cr, reflecting a 1-year growth of 27.48% and a 3-year CAGR of 9.34%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Glenmark Pharmaceuticals Ltd.?

The latest trailing twelve month net profit (PAT) of Glenmark Pharmaceuticals Ltd. is ₹ 1,361.95 Cr, with a 3-year earnings CAGR of 66.09%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Glenmark Pharmaceuticals Ltd.?

The operating margin of Glenmark Pharmaceuticals Ltd. is -. Detailed EBITDA history is available in the Income Statement section of the Statements tab.

What is the EPS of Glenmark Pharmaceuticals Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Glenmark Pharmaceuticals Ltd. is 48.26. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Glenmark Pharmaceuticals Ltd.?

The debt-to-equity ratio of Glenmark Pharmaceuticals Ltd. stands at 0.00. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Glenmark Pharmaceuticals Ltd.?

The estimated book value per share of Glenmark Pharmaceuticals Ltd. is 372.50 (derived from a P/B ratio of 5.97 and market price of ₹ 2,223.70), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Glenmark Pharmaceuticals Ltd.?

The trailing twelve month operating cash flow of Glenmark Pharmaceuticals Ltd. is ₹ 3,299.15 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Glenmark Pharmaceuticals Ltd. report consolidated or standalone financials?

Glenmark Pharmaceuticals Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.